Role of MicroRNAs and their corresponding ACE2/Apelin signaling pathways in hypertension

Ali, Farman; Shen, Aling; Islam, Waqar; Saleem, Muhammad Zubair; Muthu, Ragunath; Xie, Qiurong; Cheng, Ying; Chu, Jiangfeng; Lin, Wei; Peng, Jun

doi:10.1016/j.micpath.2021.105361

Cited by 2 publications

(1 citation statement)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypertension is a multifactorial, chronic, non-communicable disease, which is clinically described by a systolic blood pressure (SBP) ≥ 140 mmHg and a diastolic blood pressure (DBP) ≥ 90 mmHg [ 1 ]. It is partly attributed to genetic and epigenetic factors [ 2 ], as well as other non-modifiable (i.e., sex and nationality) and modifiable factors (i.e., lifestyle patterns and dietary habits) [ 3 , 4 ]. It constitutes a public health burden and a major cause of morbidity worldwide due to its implication in cardiovascular and chronic kidney diseases [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients

Tsota,

Giardoglou,

Mentsiou-Nikolaou

et al. 2024

ncRNA

View full text Add to dashboard Cite

Hypertension is a chronic, multifactorial disease, leading to high cardiovascular morbidity and mortality globally. Despite the advantages of pharmaceutical treatments, natural products have gained scientific interest due to their emerging phytotherapeutic properties. Chios mastic is a natural Greek product, consisting of bioactive compounds which modify microRNAs’ (small, expression-regulating molecules) expression. In this study, we investigated the antihypertensive properties of Chios mastic through the assessment of miR-21 levels. Herein, plasma samples of 57 individuals with hypertension, recruited for the purposes of the HYPER-MASTIC study, were analyzed. This was a clinical trial with Chios mastic supplements in which the patients were divided into groups receiving high and low mastic doses and placebo supplements, respectively. miR-21 was significantly upregulated in patients compared to normotensive individuals. Mean changes in miR-21 levels were statistically significant, after adjusting for sex and age, between the placebo and low-dose group and between the low- and high-dose group. Post-intervention miR-21 levels were positively associated with night-time systolic blood pressure, pulse pressure, and central systolic mean arterial pressure and negatively associated with night-time pulse wave velocity in the low-dose group. Our findings suggest a potential implication of miR-21 in the association of Chios mastic with night-time blood pressure measurements.

show abstract

Section: Introductionmentioning

confidence: 99%

Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients

Tsota,

Giardoglou,

Mentsiou-Nikolaou

et al. 2024

ncRNA

View full text Add to dashboard Cite

show abstract

The pharmaco-epigenetics of hypertension: a focus on microRNA

Yaacoub,

Boudaka,

AlKhatib

et al. 2024

Mol Cell Biochem

View full text Add to dashboard Cite

Hypertension is a major harbinger of cardiovascular morbidity and mortality. It predisposes to higher rates of myocardial infarction, chronic kidney failure, stroke, and heart failure than most other risk factors. By 2025, the prevalence of hypertension is projected to reach 1.5 billion people. The pathophysiology of this disease is multifaceted, as it involves nitric oxide and endothelin dysregulation, reactive oxygen species, vascular smooth muscle proliferation, and vessel wall calcification, among others. With the advent of new biomolecular techniques, various studies have elucidated a gaping hole in the etiology and mechanisms of hypertension. Indeed, epigenetics, DNA methylation, histone modification, and microRNA-mediated translational silencing appear to play crucial roles in altering the molecular phenotype into a hypertensive profile. Here, we critically review the experimentally determined associations between microRNA (miRNA) molecules and hypertension pharmacotherapy. Particular attention is given to the epigenetic mechanisms underlying the physiological responses to antihypertensive drugs like candesartan, and other relevant drugs like clopidogrel, aspirin, and statins among others. Furthermore, how miRNA affects the pharmaco-epigenetics of hypertension is especially highlighted.

show abstract

Role of MicroRNAs and their corresponding ACE2/Apelin signaling pathways in hypertension

Cited by 2 publications

References 129 publications

Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients

Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients

The pharmaco-epigenetics of hypertension: a focus on microRNA

Contact Info

Product

Resources

About